Sugi Min MD

Cardiology🫀fellow at @BrownMedicine. @ColumbiaMed

[Sugi Min MD @Sugi_Min]

Strong mentorship @BrownCardiology! Thank you @SarasVallabhMD @ACCinTouch for the opportunity to share an important trial in the CCU/MCS realm!

[Saraschandra Vallabhajosyula, MD MSc @SarasVallabhMD]

Congratulations to our amazing @BrownCardiology fellow, @Sugi_Min for his thoughtful commentary on the #AltShock2 trial for @ACCinTouch - https://t.co/viXItCYJh2. @BrownUnivHealth @BrownMedicine

[Sugi Min MD @Sugi_Min]

@Babar_Basir @SrihariNaiduMD ✋ Here and appreciating all the teaching!

[Sugi Min MD @Sugi_Min]

@RichSekerakMD @ccijournal @drmeghaprasad Congrats, game changing work Dr. Sekerak!

[Sugi Min MD @Sugi_Min]

@timpotsMD @CircAHA @echofirst @PierreEliasMD Incredible stuff, thanks @timpotsMD @PierreEliasMD for leading the way!

[ARCHIVED - NASA Moon @NASAMoon]

Oops I did it again 🤭

#TotalSolarEclipse

[Sugi Min MD @Sugi_Min]

First trial assessing prophylactic PCI in patients with non-flow limiting, vulnerable plaques (via IVUS) showed DECREASED cardiac events at 2 years! 0.4% vs. 3.4% in medical therapy alone group. Composite outcome of cardiac death, TV MI, TVR, 🏥 for UA

[Duk-Woo Park @dukwoo_park]

A long-waited PREVENT trial is now presented at LBCT-V #ACC2024
🇰🇷From the inception of trial to completion of trial took a decade.
✅1,606 pts with intracoronary imaging-detected “Vulnerable Plaque” randomized 1:1 to (1) Preventive PCI vs (2) OMT alone.
✅Prevent PCI significantly reduce primary composite endpoint (CV death, TV-MI, TVR, hospitalization for UA) at 2 yr. The effect of Preventive PCI was sustained up to 7 years.
✅First RCT shows that Preventive PCI is effective for non-flow limiting vulnerable atherosclerosis coronary plaque.
✅We believe that PREVENT would be one of the seminal investigations in the history of PCI.
@dukwoo_park @GreggWStone @JungMinAhn5 @DFCapodanno @djc795 @TheLancet
Further details:
https://t.co/R2NJ0dsdML

[Duk-Woo Park @dukwoo_park]

A long-waited PREVENT trial is now presented at LBCT-V #ACC2024
🇰🇷From the inception of trial to completion of trial took a decade.
✅1,606 pts with intracoronary imaging-detected “Vulnerable Plaque” randomized 1:1 to (1) Preventive PCI vs (2) OMT alone.
✅Prevent PCI significantly reduce primary composite endpoint (CV death, TV-MI, TVR, hospitalization for UA) at 2 yr. The effect of Preventive PCI was sustained up to 7 years.
✅First RCT shows that Preventive PCI is effective for non-flow limiting vulnerable atherosclerosis coronary plaque.
✅We believe that PREVENT would be one of the seminal investigations in the history of PCI.
@dukwoo_park @GreggWStone @JungMinAhn5 @DFCapodanno @djc795 @TheLancet
Further details:
https://t.co/R2NJ0dsdML

[Sugi Min MD @Sugi_Min]

#DanGer trial: a big win, not only for excellently named clinical trials, but for evidence of mortality benefit of Impella in STEMI-cardiogenic shock, despite increased complications! #ACC24 #impella

[Robert W. Yeh @rwyeh]

Astonishing results from the DanGer Shock Trial presented at #ACC24 and out in @NEJM today.

In patients with ST-elevation MI with cardiogenic shock, Impella reduced all-cause mortality (45.8% Impella vs. 58.5% control) at 180 days.

Some thoughts on this ground breaking trial:

[Sugi Min MD @Sugi_Min]

@Slade_Mellgard @Hemasphere_EHA @rajshekharucms Nice work Dr @Slade_Mellgard and Dr. @MollyGilligan1

[Sugi Min MD @Sugi_Min]

Celebrating #TaylorSwift #SuperBowl win with a #Jazz version. I.e. Venn diagram of Taylor Swift and Smooth jazz fans?

[Sugi Min MD @Sugi_Min]

@DanSnyder01 @djc795 @MVMadhavanMD @JWMoses Great work, insightful stuff Dr. Snyder!

[Sugi Min MD @Sugi_Min]

Thanks @EuroInterventio

[EuroIntervention @EuroInterventio]

The PROTECT III study focuses on a population of patients requiring prolonged mechanical circulatory support after Impella-supported HR-PCI, observing outcomes like complications and mortality, and emphasizing the need for tailored management strategies by specialized teams. https://t.co/iB1rMVmXaF

[Sugi Min MD @Sugi_Min]

@CharlesFoxIV I owe you for putting me on the right path!

[Babar Basir @Babar_Basir]

@Sugi_Min @EuroInterventio @JWMoses Great work @Sugi_Min !!! More insights should be provided by the #ProtectIV and datasets where PAC were used more often.

[Sugi Min MD @Sugi_Min]

@Babar_Basir @EuroInterventio @JWMoses PROTECT IV will change the field! Appreciate your mentorship and looking forward to future collaboration!

[Sugi Min MD @Sugi_Min]

1. After high-risk PCI with Impella support, which patients get transferred to the CCU for prolonged MCS, and how do they compare with patients who don't need prolonged MCS? A 🧵on our new sub-analysis of PROTECT III in @EuroInterventio with @Babar_Basir @JWMoses and team... 1/5

[Sugi Min MD @Sugi_Min]

@DanSnyder01 @EuroInterventio @Babar_Basir @JWMoses Thanks bro we getting it done

[Sugi Min MD @Sugi_Min]

Clinical characteristics and outcomes of patients requiring prolonged mechanical circulatory support after high-risk percutaneous coronary intervention via @EuroInterventio https://t.co/9oFlnlYp7I

[Sugi Min MD @Sugi_Min]

5. Sincere thanks to our amazing collaborators esp @Babar_Basir @JWMoses and team at @crfheart!! @AlejandroLemor @abu_much @agtruesdell @adityadoc1 @DrCindyGrines @RameshDaggubati @BillONeillMD @Abiomed (5/5)

[Sugi Min MD @Sugi_Min]

2. PROTECT III is a multicenter study on Impella 2.5 and CP outcomes in HR-PCI in the US. In 1,237 pts undergoing MCS-supported HR-PCI, 16% had MCS support post-procedure, and more likely to be non-White, had urgent indications (ACS), ‼️ vitals, and had more complications (2/5)